![Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle](https://www.globallegalchronicle.com/wp-content/uploads/2021/04/puma-biotechnology-and-pierre-fabres-amendment-of-nerlynx-license-agreement_6088fc8c69d82-480x360.jpeg)
Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
![These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017 These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=ner00-0019-05.jpg&id=574036)
These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017
![Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia](https://www.newshubasia.com/wp-content/uploads/2021/02/puma_logo_JPEG.jpg)
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia
![Puma Biotechnology Files NDS for Nerlynx in Canada | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Puma Biotechnology Files NDS for Nerlynx in Canada | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](http://media.americanpharmaceuticalreview.com/m/28/article/352354-333x250.jpg)
Puma Biotechnology Files NDS for Nerlynx in Canada | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
![Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire](https://mms.businesswire.com/media/20220112005882/en/1326629/22/4357884cpuma_logo_JPEG.jpg)
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
![Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD](https://www.investors.com/wp-content/uploads/2017/11/Stock-biotech-09-adobe.jpg)
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
![Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review](https://www.pharmaceutical-business-review.com/wp-content/uploads/2019/01/deal-1.jpg)
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
![Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/5/49102172_15591559956443_rId6.png)